UBS Maintains Buy on Perspective Therapeutics, Lowers Price Target to $7

Perspective Therapeutics, Inc. Common Stock -0.60%

Perspective Therapeutics, Inc. Common Stock

CATX

2.50

-0.60%

UBS analyst David Dai maintains Perspective Therapeutics (AMEX: CATX) with a Buy and lowers the price target from $18 to $7.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via